CLL-Current and Emerging Therapies

Article

Please join us for our upcoming telephone/web education program, CLL- Current and Emerging Therapies on, Wednesday, June 18, 2014 1:00-2:30 pm EST featuring Thomas Kipps, MD, Deputy Director for Research at the University of California Moores Cancer Center.

Thomas Kipps, MD

Please join us for our upcoming telephone/web education program,

CLL- Current and Emerging Therapies

on, Wednesday, June 18, 2014 1:00-2:30 pm EST featuring Thomas Kipps, MD, Deputy Director for Research at the University of California Moores Cancer Center.

Topics will include:

  • The goal of CLL treatment
  • How staging influences personalized treatment planning
  • Current treatment options for CLL
  • Emerging therapies and clinical trials for CLL
  • Side effects management
  • The importance of open communication with your treatment team

For more information, please contact the Leukemia & Lymphoma’s Information Resource Center at 800-955-4572 or

www.LLS.org/programs

.

Related Videos
Elizabeth Aronson
Shivani Gopalsami
Donna Catamero
Verina on Tackling Neurological Toxicities From CAR T-Cell Therapy
Sherry Adkins Talks Primary Care Provider Communication Following CAR T-cell Therapy
Gretchen McNally Speaks to the Role of Oncology Nurses in the Opioid Epidemic
Related Content
Zanubrutinib May Affect the Heart Less Than Ibrutinib and Acalabrutinib in CLL/SLL

Zanubrutinib May Affect the Heart Less Than Ibrutinib and Acalabrutinib in CLL/SLL

April 19th 2024
Article

Zanubrutinib to treat chronic lymphocytic leukemia or small lymphocytic lymphoma was linked with fewer cardiac adverse effects compared with ibrutinib and acalabrutinib.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit

Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit

April 12th 2024
Article

Over the last 5 years, 57% of drugs approved by the FDA for a cancer-related indication did not show a clinical benefit in confirmatory studies.

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

December 1st 2023
Podcast

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

Frontline Ibrutinib May Be Effective and Well Tolerated in Low-Risk MCL

Frontline Ibrutinib May Be Effective and Well Tolerated in Low-Risk MCL

April 4th 2024
Article

Findings from this study demonstrated effectiveness with frontline ibrutinib in patients with previously treated, low-risk mantle cell lymphoma regardless of whether rituximab was added.

FDA Approval of Oncology Drugs in March 2024

FDA Approval of Oncology Drugs in March 2024

April 1st 2024
Article

Throughout March, the FDA has approved drugs for the treatment of disease including lung, hematologic, esophageal, and gynecologic cancers.

© 2024 MJH Life Sciences

All rights reserved.